102 related articles for article (PubMed ID: 7803290)
1. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH).
Garicochea B; van Rhee F; Spencer A; Chase A; Lin F; Cross NC; Goldman JM
Br J Haematol; 1994 Oct; 88(2):400-2. PubMed ID: 7803290
[TBL] [Abstract][Full Text] [Related]
2. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia.
Keil F; Haas OA; Fritsch G; Kalhs P; Lechner K; Mannhalter C; Reiter E; Niederwieser D; Hoecker P; Greinix HT
Blood; 1997 May; 89(9):3113-7. PubMed ID: 9129013
[TBL] [Abstract][Full Text] [Related]
3. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
[TBL] [Abstract][Full Text] [Related]
6. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan JM; Duggan C; De Arce M; McCann SR
Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312
[TBL] [Abstract][Full Text] [Related]
8. Red blood cell phenotyping is a sensitive technique for monitoring chronic myeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion.
Schaap N; Schattenberg A; Bär B; Mensink E; de Man A; Geurts van Kessel A; de Witte T
Br J Haematol; 2000 Jan; 108(1):116-25. PubMed ID: 10651734
[TBL] [Abstract][Full Text] [Related]
9. The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML).
Marmont AM
Leuk Lymphoma; 1993; 11 Suppl 1():221-6. PubMed ID: 8251900
[TBL] [Abstract][Full Text] [Related]
10. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
[TBL] [Abstract][Full Text] [Related]
11. [Complete cytogenetic response obtained with unrelated donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation].
Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2001 Mar; 42(3):204-8. PubMed ID: 11345783
[TBL] [Abstract][Full Text] [Related]
12. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
13. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant.
Carrara RC; Orellana MD; Fontes AM; Palma PV; Kashima S; Mendes MR; Coutinho MA; Voltarelli JC; Covas DT
Braz J Med Biol Res; 2007 Jan; 40(1):57-67. PubMed ID: 17224997
[TBL] [Abstract][Full Text] [Related]
15. Mixed chimerism of bone marrow vessels (endothelial cells, myofibroblasts) following allogeneic transplantation for chronic myelogenous leukemia.
Kvasnicka HM; Wickenhauser C; Thiele J; Varus E; Hamm K; Beelen DW; Schaefer UW
Leuk Lymphoma; 2003 Feb; 44(2):321-8. PubMed ID: 12688352
[TBL] [Abstract][Full Text] [Related]
16. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
17. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
Castro FA; Palma PV; Morais FR; Voltarelli JC
Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
[TBL] [Abstract][Full Text] [Related]
18. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
19. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
20. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation.
Helg C; Starobinski M; Jeannet M; Chapuis B
Leuk Lymphoma; 1998 Apr; 29(3-4):301-13. PubMed ID: 9684928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
